Table 2 Background characteristics for all recruited ovarian cancer patients
From: Loss of Programmed cell death 4 (Pdcd4) associates with the progression of ovarian cancer
Characteristic | Borderline (n = 16) | Carcinoma (n = 93) |
|---|---|---|
Age | 43 (± 15) | 50 (± 12) |
stage | Â | Â |
1 | 10 (62.5) | 30 (32.2) |
2 | 1 (6.3) | 15 (16.1) |
3 | 2 (1.3) | 37 (39.8) |
4 | 0 | 9 (9.7) |
unstaged | 3 (18.8) | 1 (1.1) |
unknown stage | Â | 1 (1.1) |
Histology | Â | Â |
Endometrioid | Â | 25 (26.9) |
Mucinous | 13 (81.3) | 10 (10.7) |
Serous papillary | 3(18.7) | 29 (31.2) |
Clear cell | Â | 14 (15.0) |
Mixed | Â | 12 (12.9) |
Undifferentiated | Â | 3 (3.2) |
Number of recurrences | 5 (31.2) | 35 (37.6) |
Number of persistent disease | 0 | 14 (15.0) |
Disease-free interval (months) | 49 (30-110) | 28 (6-79) |
Overall survival time (months) | 56 (40-110) | 46 (24-97) |
With platinum treatment | 1 (6.3) | 70 (75.3) |
   Sensitive to platinum | 1 (100) | 54 (77.1) |
   Resistant to platinum |  | 16 (22.9) |
Without platinum treatment | 15 (93.7) | 23 (9.1) |